ClinicalTrials.gg
CompletedNCT06591845Updated Jun 22, 2026

Thorough QT/QTc (TQT) Clinical Study to Evaluate the Effects of Ziresovir on Cardiac Repolarization in Healthy Subjects

A Phase 1 interventional study of Ziresovir 125 mg and Ziresovir 500 mg in Healthy Volunteers, sponsored by Shanghai Ark Biopharmaceutical Co., Ltd.. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-22.

Sponsored by Shanghai Ark Biopharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2024, 1 year 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

This is a single-center, randomized, partially double-blind, placebo and active-controlled, 4-period crossover design thorough QT/QTc (TQT) clinical study to evaluate the effects of ziresovir on cardiac repolarization in healthy subjects.

Read the detailed description

This clinical study is a single-center, randomized, partially double-blind, placebo- and active-controlled, four-period crossover design, with healthy subjects comprising the enrolled population. Ziresovir and placebo will be administered in a double-blind manner, while moxifloxacin hydrochloride tablets will be administered in as open-label.

Thirty-two subjects meeting all inclusion criteria and none of the exclusion criteria will be randomized into 1 of 12 dosing sequences, each consisting of 4 periods with an 8-day washout period in-between.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • QT/QTc (TQT) Clinical Study
03

In context

Lead sponsor

Shanghai Ark Biopharmaceutical Co., Ltd. is the lead sponsor of 20 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The subject voluntarily signed a written form.
  2. Male or female; between 18 and 50 years old (inclusive).
  3. Male subjects weighing ≥50 kg, female subjects weighing ≥45 kg, (BMI) between 19.0 and 30.0 kg/m2 (inclusive), BMI= weight (kg)/height2 (m2).
  4. Healthy, as defined by no or relevant abnormalities identified by vital signs, physical examination, laboratory examination items, , and other trial-related examinations at screening, admission or baseline day of each period as assessed by the investigator.
  5. The subject can communicate well with the investigator and is able to complete the study in compliance with the protocol.

Exclusion criteria

Exclusion Criteria:

  1. History of or evidence of disorder, condition or disease not otherwise excluded that, in the opinion of the investigator, would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion.
  2. History of cardiovascular disease or risk factors for Torsade de Pointes (TdP) at screening, including but not limited to: unexplained syncope; heart failure; cardiomyopathy; hypertension; angina pectoris; myocardial infarction; hypokalemia; bradycardia or sick sinus syndrome; cardiac conduction abnormalities; personal or family history of long syndrome (LQTS); or family history of sudden death.
  3. Known or suspected .
  4. Known allergic reactions to study intervention (e.g., ziresovir or its drug , moxifloxacin, fluoroquinolone antibiotics) or history of clinically significant multiple or severe drug allergies, food allergies.
  5. Subjects who have donated blood or have had a blood loss ≥500 ml within 3 months prior to screening.
  6. Subjects who have participated in a clinical trial evaluating an drug or device within 30 days or 5 half-lives (whichever is longer) prior to screening.
  7. History of substance abuse (e.g., alcohol, licit or illicit drugs) within 1 year prior to screening.
  8. 12-lead at screening or admission exceeding criteria: PR\>220 ms, QRS\>120 ms, HR\< 50 bpm or \>100 bpm, QTcF \>450 ms (male and female) (The mean of 3 triplicate ECGs timepoint measurement); or ECG abnormalities that are considered by the investigator to be abnormal and clinically significant.
  9. Systolic blood pressure (BP) \> 140 mmHg or \< 90 mmHg, or diastolic BP \> 90 mmHg at screening or admission.
  10. Serum potassium, calcium, or magnesium levels outside the normal range at screening or admission.
  11. Positive blood alcohol test, positive urine cotinine test or positive urine drug abuse screening at screening or admission.
  12. Engaged in strenuous exercise within 48 hours before randomization (e.g., marathon running, long-distance cycling, weightlifting).
  13. Intake of caffeinated beverages or food within 48 hours before randomization or a history of high caffeine consumption (e.g., in the last 3 months drinking \>5 cups of coffee/day).
  14. History of alcoholism or regular alcohol consumption within 1 year prior to screening, defined as more than 14 units (male) or 7 units (female) of alcohol per week (1 unit =360 mL of beer or 45 mL of spirits containing 40% alcohol or 150 mL of wine).
  15. Smoking or use of tobacco or nicotine-containing products within 6 months before screening.
  16. Pregnant or lactating women or those with positive blood pregnancy test results.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    Treatment T (Therapeutic dose)

    The subjects will receive a ziresovir 125 mg as single dose on Day 1 (Period 1) or Day 9 (Period 2) or Day 17 (Period 3) or Day 25 (Period 4)

    Drug: Ziresovir 125 mg

  • Experimental
    Treatment ST (Supratherapeutic dose)

    The subjects will receive a ziresovir 500 mg as single dose on Day 1 (Period 1) or Day 9 (Period 2) or Day 17 (Period 3) or Day 25 (Period 4)

    Drug: Ziresovir 500 mg

  • Placebo comparator
    Treatment P (Placebo)

    The subjects will receive a placebo as single dose on Day 1 (Period 1) or Day 9 (Period 2) or Day 17 (Period 3) or Day 25 (Period 4)

    Drug: Placebo

  • Active comparator
    Treatment PC (positive control)

    The subjects will receive a moxifloxacin hydrochloride tablet 400 mg as single dose on Day 1 (Period 1) or Day 9 (Period 2) or Day 17 (Period 3) or Day 25 (Period 4)

    Drug: Moxifloxacin hydrochloride tablet 400 mg

Interventions

  • Active Substance: Ziresovir, Pharmaceutical Form: Suspension, Route of Administration: Oral

  • Active Substance: Ziresovir, Pharmaceutical Form: Suspension, Route of Administration: Oral

  • DrugPlacebo

    Active Substance: Placebo, Pharmaceutical Form: Suspension, Route of Administration: Oral

  • Active Substance: Moxifloxacin hydrochloride Pharmaceutical Form: Tablet Route of Administration: Oral

06

What researchers measure

Primary outcomes

  1. Change from baseline QTcF (ΔQTcF)

    The primary ECG endpoint is the change from baseline in the QT interval corrected for heart rate (HR) using the Fridericia method (ΔQTcF).

    Time frame: Before dosing (Baseline) through 48 hours after the dose on Day 1 in each treatment period

Secondary outcomes

  1. Change from baseline in QTc

    Change from baseline in QTc using correction methods not chosen as the primary correction method if a substantial HR effect is observed

    Time frame: Before dosing (Baseline) through 48 hours after the dose on Day 1 in each treatment period

  2. Change from baseline in HR, PR, and QRS

    Change-from-baseline in HR, PR and QRS (ΔHR, ΔPR and ΔQRS).

    Time frame: Before dosing (Baseline) through 48 hours after the dose on Day 1 in each treatment period

  3. Incidence of treatment-emergent adverse events (TEAEs) and changes in laboratory safety tests, vital signs, and ECGs.

    Incidence of treatment-emergent adverse events (TEAEs) and changes in laboratory safety tests, vital signs, and ECGs.

    Time frame: Up to Day 8 of each treatment period (up to 31 days)

  4. Treatment-emergent changes in ECG Morphology

    Treatment-emergent changes in ECG Morphology

    Time frame: Before dosing (Baseline) through 48 hours after the dose on Day 1 in each treatment period

  5. Categorical outliers for QTcF/QTcI/QTcS, HR, PR, and QRS.

    Categorical outliers for QTcF/QTcI/QTcS, HR, PR, and QRS.

    Time frame: Before dosing (Baseline) through 48 hours after the dose on Day 1 in each treatment period

  6. Maximum observed plasma concentration (Cmax) of ziresovir

    PK parameters of ziresovir and its metabolites including maximum observed plasma concentration (Cmax).

    Time frame: Pre-dose within 1 hour and at 0.5 hour, 1 hour, 2 hours, 3 hours, 4 hours, 8 hours, 12 hours, 24 hours, 36 hours, 48 hours, and 72 hours post-dose during each period

  7. Terminal elimination half-life (t1/2) of ziresovir.

    PK parameters of ziresovir and its metabolites including terminal elimination half-life (t1/2).

    Time frame: Pre-dose within 1 hour and at 0.5 hour, 1 hour, 2 hours, 3 hours, 4 hours, 8 hours, 12 hours, 24 hours, 36 hours, 48 hours, and 72 hours post-dose during each period.

  8. Area under the curve (AUC) of ziresovir.

    PK parameters of ziresovir and its metabolites including area under the curve (AUC).

    Time frame: Pre-dose within 1 hour and at 0.5 hour, 1 hour, 2 hours, 3 hours, 4 hours, 8 hours, 12 hours, 24 hours, 36 hours, 48 hours, and 72 hours post-dose during each period.

07

Study locations

1 site
  • California Clinical Trials Medical Group, Inc.
    Glendale, California 91206, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2024 to primary completion in Dec 2024, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2024
First posted
Sep 19, 2024
StartActual
Sep 25, 2024
Primary completionActual
Dec 16, 2024
CompletionActual
Dec 23, 2024
Last update
Jun 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06591845
Lead sponsor
Shanghai Ark Biopharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
Sep 25, 2024
Primary completion
Dec 16, 2024
Completion
Dec 23, 2024
Last update
Jun 22, 2026

Study contacts

David Han, M.D., M.P.H
principal investigator · California Clinical Trials Medical Group

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ziresovir

Start the discussion